Aussie-led stroke study gets funding boost
5th November 2014
The clot-busting drug tenecteplase is one step closer to becoming a first-line stroke treatment after receiving more than $3 million in NHMRC funding.
The tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE) phase III trial is the top neurology grant from the NHMRC for 2015. Altogether, grants involving neurology received more than $30 million out of the $540 million pool
The tenecteplase
